CStone targets European expansion with EMA filing for Sugemalimab in stage III NSCLC
CStone Pharmaceuticals seeks EMA approval for sugemalimab in stage III NSCLC, aiming to expand lung cancer immunotherapy options in Europe. Read More
CStone Pharmaceuticals partners with SteinCares to expand cancer treatment in Latin America
CStone Pharmaceuticals, a leading biopharmaceutical company specializing in innovative cancer therapies, has entered a landmark partnership with SteinCares, a Latin American pharmaceutical leader. This collaboration ... Read More
CStone Pharmaceuticals receives positive CHMP opinion for Sugemalimab in NSCLC treatment
CStone Pharmaceuticals (HKEX: 2616), a leading innovation-driven biopharmaceutical company from China, announced a significant milestone with the Committee for Medicinal Products for Human Use (CHMP) ... Read More
CStone’s sugemalimab gains CHMP recommendation for NSCLC treatment
CStone Pharmaceuticals has reached a pivotal milestone in its global strategy, with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ... Read More
CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer
US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological ... Read More